全文获取类型
收费全文 | 184016篇 |
免费 | 68681篇 |
国内免费 | 2335篇 |
专业分类
耳鼻咽喉 | 3449篇 |
儿科学 | 6670篇 |
妇产科学 | 3045篇 |
基础医学 | 19662篇 |
口腔科学 | 10016篇 |
临床医学 | 37773篇 |
内科学 | 47389篇 |
皮肤病学 | 10456篇 |
神经病学 | 23815篇 |
特种医学 | 6032篇 |
外国民族医学 | 3篇 |
外科学 | 31963篇 |
综合类 | 4619篇 |
现状与发展 | 49篇 |
一般理论 | 28篇 |
预防医学 | 18200篇 |
眼科学 | 3805篇 |
药学 | 9292篇 |
30篇 | |
中国医学 | 2983篇 |
肿瘤学 | 15753篇 |
出版年
2024年 | 893篇 |
2023年 | 5569篇 |
2022年 | 2434篇 |
2021年 | 5584篇 |
2020年 | 11568篇 |
2019年 | 13550篇 |
2018年 | 15949篇 |
2017年 | 17713篇 |
2016年 | 18467篇 |
2015年 | 18944篇 |
2014年 | 21516篇 |
2013年 | 23912篇 |
2012年 | 9069篇 |
2011年 | 8788篇 |
2010年 | 15877篇 |
2009年 | 14554篇 |
2008年 | 6350篇 |
2007年 | 4100篇 |
2006年 | 5223篇 |
2005年 | 3427篇 |
2004年 | 2616篇 |
2003年 | 2231篇 |
2002年 | 2183篇 |
2001年 | 3062篇 |
2000年 | 2190篇 |
1999年 | 2211篇 |
1998年 | 2168篇 |
1997年 | 1962篇 |
1996年 | 2011篇 |
1995年 | 1754篇 |
1994年 | 1126篇 |
1993年 | 948篇 |
1992年 | 892篇 |
1991年 | 725篇 |
1990年 | 608篇 |
1989年 | 593篇 |
1988年 | 580篇 |
1987年 | 455篇 |
1986年 | 428篇 |
1985年 | 369篇 |
1984年 | 333篇 |
1983年 | 343篇 |
1982年 | 254篇 |
1981年 | 215篇 |
1980年 | 138篇 |
1979年 | 109篇 |
1978年 | 155篇 |
1977年 | 149篇 |
1976年 | 108篇 |
1974年 | 105篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
目的 对比研究朝鲜淫羊藿酸性多糖酯化还原前后的理化特性,并探讨其改善油酸诱导的肝癌HepG2细胞脂质堆积活性的差异。方法 采用高效凝胶渗透色谱法测定朝鲜淫羊藿酸性多糖(EFPA)的均一性和分子量,高效液相色谱法测定EFPA和酯化还原后朝鲜淫羊藿酸性多糖(EFPA-R)的单糖组成;采用油酸(OA)处理HepG2细胞诱导建立脂质蓄积模型,不同浓度EFPA与EFPA-R(10、30、100、300 μg·mL-1)分别和OA共同作用于细胞24 h,采用CCK-8试剂盒测定细胞存活率,油红O染色观察细胞内脂滴蓄积情况,并采用试剂盒测定细胞内总胆固醇(TC)、甘油三酯(TG)含量。结果 EFPA为成分均一的多糖组分,分子量为125.8 kDa,由甘露糖、葡萄糖、半乳糖、葡萄糖醛酸和阿拉伯糖组成,摩尔比为1.7∶7.4∶1.4∶1.8∶1.0,葡萄糖占比最大,EFPA-R由甘露糖、葡萄糖、半乳糖和阿拉伯糖组成,摩尔比为0.8∶10.6∶2.1∶1.0;在10-300 μg·mL-1范围内,EFPA和EFPA-R对HepG2细胞的抑制作用较弱,作为给药浓度;与空白组相比,模型组细胞中TC、TG含量显著升高(P < 0.01),细胞内红色脂滴显著增多,与模型组相比,EFPA可显著降低细胞中TC、TG含量(P < 0.01),明显减少细胞内红色脂滴(P < 0.05或P < 0.01),EFPA-R干预后细胞则无明显变化。结论 EFPA可明显改善HepG2细胞脂质堆积情况,且呈现剂量依赖性,而半乳糖醛酸(GalA)的存在可能是其抑制HepG2细胞脂质蓄积的关键因素。 相似文献
4.
5.
6.
7.
8.
9.
10.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献